Health
Regeneron halts trial of antibody treatment in seriously ill Covid patients – Financial Times
Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases
Regeneron has stopped enrolling seriously ill Covid-19 patients in a clinical trial of the antibody treatment that US President Donald Trump has hailed as a “cure” for the disease.
Shares in Regeneron fell as much as 3 per cent after an independent data monitoring committee warned that the risks might outweigh the benefits for hospitalised patients on high levels of oxygen.
The move comes after Eli Lilly, which is also developing a Covid-19 antibody treatment, stopped its trial in hospitalised…
-
Business19 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News20 hours agoYoung voices shape Sunshine Coast’s future
-
Noosa News17 hours agoSudden death investigation, Maroochydore – Sunshine Coast
-
General23 hours agoUS stocks sink further as Donald Trump urges Americans to be ‘courageous and patient’